Intravesical treatment of overactive bladder syndrome;Intravesikale therapie des overactive-bladder-syndroms

Urologe - Ausgabe A

Volumn 45, Issue 10, 2006, Pages 1283-1288

  Haferkamp, A ^a   Hohenfellner, M ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Botulinum toxin; Capsaicin; Overactive bladder; Oxybutynin; Resiniferatoxin

Indexed keywords

BOTULINUM TOXIN A; BUPIVACAINE; CAPSAICIN; LIDOCAINE; OXYBUTYNIN; RESINIFERATOXIN; TROSPIUM CHLORIDE;

ABSENCE OF SIDE EFFECTS; BLADDER CAPACITY; BLADDER FUNCTION; HUMAN; INTERMITTENT CATHETERIZATION; OVERACTIVE BLADDER; REVIEW; SHORT COURSE THERAPY; THERAPY EFFECT; URGE INCONTINENCE;

ADMINISTRATION, INTRAVESICAL; ANESTHETICS, LOCAL; BOTULINUM TOXIN TYPE A; CHOLINERGIC ANTAGONISTS; HUMANS; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; NEUROMUSCULAR AGENTS; SYNDROME; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 33750296452     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00120-006-1178-4     Document Type: Review

References (26)

1. Apostolidis A, Popat R, Yiangou Y et al. (2005) Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174: 977-982
2. Brendler CB, Radebaugh LC, Mohler JL (1989) Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 141: 1350-1352
3. Buyse G, Waldeck K, Verpoorten C et al. (1998) Intravesical oxybutynin for neurogenic bladder dysfunction: less systemic side effects due to reduced first pass metabolism. J Urol 160: 532-534
4. Chapple CR (2000) Muscarinic antagonists in the treatment of overactive bladder. Urology 55 [Suppl 5A]: 33-46
5. De Wachter S, Wyndaele JJ (2003) Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol 169: 1892-1895
6. Dinis P, Silva J, Ribeiro MJ et al. (2004) Bladder Cfiber desensitization induces a long-lasting improvement of BPH-associated storage LUTS: a pilot study. Eur Urol 46: 88-93
7. Enzelsberger H, Schatten C, Kurz C (1991) Comparison of emepronium bromide with intravesical administration of lidocaine gel in women with urge incontinence. Geburtshilfe Frauenheilkd 51: 54-57
8. Enzelsberger H, Helmer H, Kurz CH (1995) Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial. Br J Obstet Gynaecol 102: 929-930
9. Evans RJ (2005) Intravesical therapy for overactive bladder. Curr Urol Rep 6: 429-433
10. Fowler CJ, Jewkes D, McDonald WI et al. (1992) Intravesical capsaicin for neurogenic bladder dysfunction. Lancet 339: 1239
11. Fowler CJ (2000) Intravesical treatment of overactive bladder. Urology 55 [Suppl 5A]: 60-64
12. Fröhlich G, Burmeister S, Wiedemann A, Bulitta M (1998) Intravesikale Instillation von trospiumchlorid, Oxybutynin und Verapamil zur Relaxation des Harnblasen-Detrusors. Arzneim Forsch Drug Res 48: 486-491
13. Gassner K, Briel RC (1988) Effectiveness of intravesical administration of lidocaine gel in females with urge and urge incontinence. Geburthilfe Frauenheilkd 48: 562-566
14. Guerrero K, Emery S, Owen L, Rowlands M (2006) Intravesical oxybutynin: practicalities of clinical use. J Obstet Gynaecol 26: 141-143
15. Kessler TM, Danuser H, Schumacher M et al. (2005) Botulinum A toxin injections into the detrusor: an effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 24: 231-236
16. Kuo HC (2005) Multiple intravesical instillation of low-dose resiniferatoxin is effective in the treatment of detrusoroveractivity refractory to anticholinergics. BJU Int 95: 1023-1027
17. Massad CA, Kogan BA, Trigo-Rocha FE (1992) The pharmacokinetics of intravesical and oral oxybutynin chloride. J Urol 148: 595-597
18. Palma PC, Thiel M, Riccetto CL et al. (2004) Resiniferatoxin for detrusor instability refractory to anticholinergics. Int Braz J Urol 30: 53-58
19. Popat R, Apostolidis A, Kalsi V et al. (2005) A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 174: 984-989
20. Schulte-Baukloh H, Weiss C, Stolze T et al. (2005) Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: urodynamic outcome and patient satisfaction. Urology 66: 82-87
21. Schurch B, Stohrer M, Kramer G et al. (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 163: 692-697
22. Soontrapa S, Ruksakul W, Nonthasood B, Tappayuthpijarn P (2003) The efficacy of Thai capsaicin in management of overactive bladder and hypersensitive bladder. J Med Assoc Thai 86: 861-867
23. Walter P, Grosse J, Bihr AM et al. (1999) Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: A pilot study. Neurourol Urodyn 18: 447-453
24. Werner M, Schmid DM, Schussler B (2005) Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 192: 1735-1740
25. Yokoyama O, Komatsu K, Kodama K et al. (2000) Diagnostic value of intravesical lidocaine for overactive bladder. J Urol 164: 340-343
26. Yoshimura N, Chancellor MB (2002) Current and future pharmacological treatment of overactive bladder. J Urol 168: 1897-1913